Stocktoria
Tenaya Therapeutics, Inc. TNYA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-30
Tenaya Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $68.6M | $86.7M | $98.0M | $94.5M | $54.4M |
| Operating income | -$93.3M | -$115.9M | -$131.2M | -$125.6M | -$72.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$90.6M | -$111.1M | -$124.1M | -$123.7M | -$72.7M |
| EPS (diluted) | $-0.59 | $-1.31 | $-1.68 | $-2.76 | $-4.10 |
| Operating cash flow | -$68.3M | -$90.5M | -$102.1M | -$104.4M | -$60.8M |
| Free cash flow | -$68.9M | -$91.5M | -$103.3M | -$125.1M | -$85.9M |
| Cash & equivalents | $100.5M | $4.3M | $45.7M | $95.3M | $38.1M |
| Total assets | $146.9M | $119.9M | $170.5M | $278.9M | $314.2M |
| Total liabilities | $23.7M | $27.1M | $31.1M | $35.6M | $35.7M |
| Shareholders' equity | $123.3M | $92.9M | $139.4M | $243.4M | $278.5M |
Source: SEC EDGAR filings · CIK 0001858848 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.